|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 2, 2005
Department of Pharmacology and Toxicology, University of California, Davis, Davis, CA 95616
Corresponding Author: mewright{at}ucdavis.edu
The maturation of mass spectrometry technologies has provided a rich opportunity to interrogate protein expression patterns in normal and disease states by applying expression protein profiling methods. Major goals of this research strategy include the identification of protein biomarkers that demarcate normal and disease populations, and the identification of therapeutic biomarkers for the treatment of diseases such as cancer [1]. Prostate cancer is one disease that would greatly benefit from implementing mass spectrometry based expression profiling methods because of the need to stratify the disease based on molecular markers. In this review article will summarize the current mass spectrometry based methods to identify and validate biomarkers in human prostate cancer. Lastly, we propose a reverse proteomic approach implementing a quantitative mass spectrometry research strategy to identify and quantify biomarkers implicated in prostate cancer development. With this approach, the absolute levels of prostate cancer biomarkers will be identified and quantified in normal and disease samples by measuring the levels of native peptide biomarkers in relation to a chemically identical, but isotopically labeled reference peptide. Ultimately, a centralized prostate cancer peptide biomarker expression database could function as a repository for the identification, and validation of protein biomarker(s) during prostate cancer progression
Revised on February 2, 2005
Accepted on February 2, 2005
Mass spectrometry based expression profiling of clinical prostate cncer
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
R. R. Drake, E. E. Schwegler, G. Malik, J. Diaz, T. Block, A. Mehta, and O. J. Semmes Lectin Capture Strategies Combined with Mass Spectrometry for the Discovery of Serum Glycoprotein Biomarkers Mol. Cell. Proteomics, October 1, 2006; 5(10): 1957 - 1967. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-J. Qian, J. M. Jacobs, T. Liu, D. G. Camp II, and R. D. Smith Advances and Challenges in Liquid Chromatography-Mass Spectrometry-based Proteomics Profiling for Clinical Applications Mol. Cell. Proteomics, October 1, 2006; 5(10): 1727 - 1744. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-L. Wu, J. Kim, R. W. Bandle, L. Liotta, E. Petricoin, and B. L. Karger Dynamic Profiling of the Post-translational Modifications and Interaction Partners of Epidermal Growth Factor Receptor Signaling after Stimulation by Epidermal Growth Factor Using Extended Range Proteomic Analysis (ERPA) Mol. Cell. Proteomics, September 1, 2006; 5(9): 1610 - 1627. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Canas, D. Lopez-Ferrer, A. Ramos-Fernandez, E. Camafeita, and E. Calvo Mass spectrometry technologies for proteomics Brief Funct Genomic Proteomic, February 1, 2006; 4(4): 295 - 320. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Journal of Biological Chemistry |
| Journal of Lipid Research | ASBMB Today |